Provided by Tiger Fintech (Singapore) Pte. Ltd.

Urogen Pharma Ltd.

20.47
+0.62003.12%
Post-market: 20.470.00000.00%19:25 EDT
Volume:813.55K
Turnover:16.51M
Market Cap:947.03M
PE:-6.24
High:20.72
Open:19.99
Low:19.74
Close:19.85
52wk High:21.71
52wk Low:3.42
Shares:46.26M
Float Shares:37.03M
Volume Ratio:0.86
T/O Rate:2.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2780
EPS(LYR):-2.9590
ROE:-1481.26%
ROA:-31.21%
PB:-10.14
PE(LYR):-6.92

Loading ...

UroGen Pharma Ltd. to Release Third Quarter 2025 Results

Reuters
·
Oct 30

Analysts’ Top Healthcare Picks: Urogen Pharma (URGN), AngioDynamics (ANGO)

TIPRANKS
·
Oct 27

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 27

UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues

Simply Wall St.
·
Oct 06

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 03

UroGen Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

Reuters
·
Oct 02

Jason Drew Smith, General Counsel, Reports Disposal of Common Shares in Urogen Pharma Ltd

Reuters
·
Sep 10

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Sep 08

UroGen Pharma Ltd. Announces Inducement Grants of Restricted Stock Units to New Employees Under 2019 Inducement Plan

Reuters
·
Sep 08

Urogen Pharma Ltd. Conducted Annual Shareholder Meeting

Reuters
·
Aug 28

UroGen Pharma Ltd. to Participate in Wells Fargo Healthcare Conference in Boston

Reuters
·
Aug 21

UroGen Pharma Initiated at Overweight by Piper Sandler

Dow Jones
·
Aug 19

Piper Sandler Initiates UroGen Pharma at Overweight With $36 Price Target

MT Newswires Live
·
Aug 19

Cardinal Health Drops in Pre-Market Trading Thursday Following $1.9 Billion Acquisition Deal

Deep News
·
Aug 14

Urogen Pharma Ltd. Chief Medical Officer Mark Schoenberg Reports Disposal of Common Shares

Reuters
·
Aug 13

Urogen Pharma Ltd reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Stock Track | UroGen Pharma Plummets 8.67% as Q2 Earnings Miss Overshadows Revenue Beat

Stock Track
·
Aug 07

Stock Track | UroGen Pharma Plunges 5.50% Pre-Market Despite Revenue Beat as Q2 Earnings Miss Estimates

Stock Track
·
Aug 07

UroGen Pharma Q2 JELMYTO revenue up 11%, beats estimates

Reuters
·
Aug 07

Earnings Flash (URGN) UroGen Pharma Posts Q2 Net Loss $1.05 a Share, vs. FactSet Est of $0.83 Loss

MT Newswires Live
·
Aug 07